DMPK and myotonic dystrophy type 1: However, the initial application of this approach in the Phase I/II clinical trial for DM1 showed that the drug concentration observed in the skeletal muscles of treated patients was not sufficient to significantly reduce the mutant DMPK mRNA, suggesting that the efficiency of AON delivery in skeletal muscle needs to be improved [16].